Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2014 - 2023)
Palvella Therapeutics' (PVLA) quarterly Depreciation & Amortization (CF) came in at -$198000.0 in Q4 2023, down 134.43% year-on-year from $575000.0 in Q4 2022, and down 126.79% on a QoQ basis from $739000.0 in Q3 2023.
Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2014 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has 10 years of Depreciation & Amortization (CF) data on file, last reported at -$198000.0 in Q4 2023.
- On a quarterly basis, Depreciation & Amortization (CF) fell 134.43% year-over-year to -$198000.0 in Q4 2023; TTM through Sep 2024 was -$198000.0, a 107.4% decrease from a year earlier, with the FY2023 full-year figure at $1.9 million, down 31.26% from the prior year.
- Depreciation & Amortization (CF) for Q4 2023 stood at -$198000.0, down from $739000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for PVLA reached as high as $845000.0 in Q1 2022 and fell as low as -$198000.0 in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $503800.0 across 5 years, with a median of $606500.0 in 2021.
- Across the five-year window, Depreciation & Amortization (CF) jumped 1161.9% in 2020 and plunged 134.43% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $265000.0 in 2019, then jumped by 159.62% to $688000.0 in 2020, then dropped by 11.48% to $609000.0 in 2021, then decreased by 5.58% to $575000.0 in 2022, then plunged by 134.43% to -$198000.0 in 2023.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were -$198000.0 in Q4 2023, $739000.0 in Q3 2023, and $758000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -198,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Dec 31, 2021 | 609,000.00 |
| Dec 31, 2021 | 609,000.00 |
| Sep 30, 2021 | 608,000.00 |
| Sep 30, 2021 | 608,000.00 |